Vivian Chua, PhD’s research focuses on strategies to improve the effectiveness of targeted therapy to treat uveal melanoma. This investigation will perform a gene expression screening method to investigate differences in the genetic profiles of BAP1-deficient and BAP1-proficient uveal melanoma cells when treated with MEK inhibitors. The study will also identify whether these cells differentially alter the levels of proteins involved in inflammation which can affect interactions between the immune system and tumor cells. This research aims to uncover mechanisms that may be exploited to improve the responses of uveal melanoma cells to MEK inhibitors and immunotherapy.